Drug Resistant Epilepsy
Felbamate
Lennox Gastaut Syndrome
Lidocaine
Seizures

Felbamate

Felbamate is an anti-epileptic drug that the Food and Drug Administration approved for the management of focal seizures and Lennox-Gastaut syndrome. It should be a consideration for patients with drug-resistant epilepsy where the benefit of seizure control outweighs the risk of severe idiosyncratic reactions. This activity focuses on the indications, mechanism of action, methods of administration, significant adverse effects, and contraindications. Additionally, this CME reviews the monitoring and toxicity of felbamate. Understanding the complex pharmacology of felbamate enables healthcare professionals to tailor treatments for a patient-centered approach. This continuing medical education (CME) activity is designed to provide essential knowledge and practical tools for the optimal administration of felbamate. This educational initiative highlights the significant role of the interprofessional healthcare team in managing felbamate therapy. The CME program aims to provide evidence-based medicine to improve patient care and outcomes. It focuses on strategies to minimize adverse reactions while maximizing the effectiveness of lidocaine. This training will equip healthcare professionals with the knowledge to deliver safe, effective, and individualized care during felbamate administration.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.